Isothiafludine

Cat. No.:	HY-111003
CAS No.:	960527-22-4
Molecular Formula:	$C_{18}H_{18}FN_3OS_2$
Molecular Weight:	375.48
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation[1].
In Vitro	Isothiafludine inhibits HBV DNA replication, with an IC_{50} of 1.33 μM[1]. Isothiafludine (8 days) shows an IC_{50} (50% cytotoxicity) of 50.4 μM against HepG2.2.15 cells[1]. Isothiafludine (1.25-20 μM, 48 h) also inhibits the replication of 3TC/ETV-dual-resistant and ADV-resistant HBV mutants in virus transfected Huh7 cells[1]. Isothiafludine (10-20 μM, 8 days) decreases the levels of encapsidated HBV pgRNA in HepG2.2.15 cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Isothiafludine (p.o., 25-100 mg/kg, for 15 days) inhibits DHBV DNA replication in a DHBV-infected duck model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DHBV-infected duck model[2]
Dosage:	25-100 mg/kg
Administration:	p.o., for 15 days
Result:	Inhibited DHBV DNA in the sera on day 15.

REFERENCES

[1]. Yang L, et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin. 2014 Mar;35(3):410-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA